Atripla
Total Payments
$53,931
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $53,931 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $53,931 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Early Antiretroviral Therapy in Resource Limited Settings in Patients with High CD4+ Cell Counts | Gilead Sciences, Inc. | $53,931 | 0 |
Top Doctors Receiving Payments for Atripla
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | La Jolla, CA | $53,931 | 1 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $53,931
Product Information
- Type Drug
- Total Payments $53,931
- Total Doctors 0
- Transactions 1
About Atripla
Atripla is a drug associated with $53,931 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences, Inc..
Payment data is available from 2018 to 2018. In 2018, $53,931 was paid across 1 transactions to 0 doctors.
The most common payment nature for Atripla is "Unspecified" ($53,931, 100.0% of total).
Atripla is associated with 1 research study, including "Early Antiretroviral Therapy in Resource Limited Settings in Patients with High CD4+ Cell Counts" ($53,931).